Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel
Roivant Sciences has recently signed a USD 650 million deal to acquire near-global rights to Poxel pharma’s phase 3-ready Type 2 diabetes drug (imeglimin). It’s been a while since Poxel was waiting for a partner capable of sharing the burden of a late-phase diabetes program. Now with the successful partnership deal, poxel can concentrate on further development of the respective drug without any financial hurdle.
PolyPid listed for another IPO shot, seeking USD 86 million as it prepares for phase 3 trails
Israeli biotech PolyPid is moving forward and has...
